A study of the reasons for prescribing and misuse of gabapentinoids in prison including their co-prescription with opioids and antidepressants. Soni A, Walters P. Int J Prison Health. 2019 Aug 27;16(1):67-77. doi: 10.1108/IJPH-01-2019-0004. Abs...

Buprenorphin-Depot: Annäherung an das Äquivalenzprinzip in Haft - Besondere Eignung von Buvidal® zur Substitutionstherapie in der JVA  Mannheim/Lund, 13.12.2019 – Die 4. Gefängnismedizintage am 5. und 6. Dezember 2019 in Frankfurt stießen au...

Gender and drug policy: Exploring global innovative approaches to drug policy and incarceration Across the Americas, drug policies have failed to make a significant dent in the drug trade, while corruption and organized crime continue to thrive. ...

Opioid-related treatment, interventions, and outcomes among incarcerated persons: A systematic review. Malta M, Varatharajan T, Russell C, Pang M, Bonato S, Fischer B (2019)  PLoS Med 16(12): e1003002. https://doi.org/10.1371/journal.pmed.1...

Longitudinal analysis of HIV-risk behaviors of participants in a randomized trial of prison-initiated buprenorphine. Blue TR, Gordon MS, Schwartz RP, Couvillion K, Vocci FJ, Fitzgerald TT, O'Grady KE. Addict Sci Clin Pract. 2019 Dec 2;14(1):45. ...

Opioid substitution therapy for people living in German prisons—inequality compared with civic sector. Stöver, H., Jamin, D., Michels, I.I. et al.  Harm Reduct J 16, 72 (2019) doi:10.1186/s12954-019-0340-4 https://harmreductionjournal.biom...